Cocrystal Pharma, Inc. (COCP) |
|
1.96 -0.07 (-3.45%)
|
09-27 16:00 |
|
Open: |
2.0701 |
Pre. Close: |
2.03 |
|
High:
|
2.1 |
Low:
|
1.93 |
|
Volume:
|
12,060 |
Market Cap:
|
20(M) |
|
|
|
Technical analysis |
as of: 2023-09-27 4:18:29 PM |
|
Short-term rate:
|
  |
| Stoxline posted a NEUTRAL today, downgraded from higher rating. Current trend continues, but could change at anytime. It is not a good time to buy or sell. |
|
Mid-term rate:
|
 |
| Target: |
Six months: 3.14 One year: 3.78 |
| Support: |
Support1: 1.79 Support2: 1.49 |
| Resistance: |
Resistance1: 2.68 Resistance2: 3.24 |
| Pivot: |
2.02 |
| Moving Average: |
MA(5): 1.99 MA(20): 2.2
MA(100): 2.5 MA(250): 2.44 |
| MACD: |
MACD(12,26): -0.2  Signal(9): -0.2 |
| Stochastic oscillator: |
%K(14,3): 26.4 %D(3): 17.4 |
| RSI: |
RSI(14): 36.6 |
| 52-week: |
High: 3.72 Low: 1.74 |
| Average Vol(K): |
3-Month: 32 (K) 10-Days: 20 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ COCP ] has closed above bottom band by 26.2%. Bollinger Bands are 57.7% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 0 bars. This is a sign that the market may be about to initiate a new trend. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
2.18 - 2.19 |
2.19 - 2.2 |
|
Low:
|
2.01 - 2.02 |
2.02 - 2.03 |
|
Close:
|
2.11 - 2.13 |
2.13 - 2.14 |
|
Company Description |
|
Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases. It employs structure-based technologies to create antiviral drugs primarily to treat hepatitis C virus (HCV), influenza virus, coronavirus, and norovirus infections. The company develops CC-31244, a HCV non-nucleoside polymerase inhibitor that has completed Phase II a clinical trial to treat HCV infection; and CC-42344, a PB2 inhibitor that is in preclinical development trials for treating influenza infection. It is also involved in identifying and developing non-nucleoside polymerase inhibitors for norovirus infections. Cocrystal Pharma, Inc. has a license and research collaboration agreement with Merck Sharp & Dohme Corp. to discover and develop proprietary influenza A/B antiviral agents; a license agreement with Kansas State University Research Foundation to develop antiviral compounds for the treatment of norovirus and coronavirus infections; and drug discovery collaboration with HitGen and InterX Inc. The company is headquartered in Bothell, Washington. |
Headline News |
Tue, 26 Sep 2023
Is Cocrystal Pharma Inc (COCP) Stock About to Get Hot Tuesday? - InvestorsObserver
Mon, 14 Aug 2023
Cocrystal Pharma Reports Second Quarter 2023 Financial Results and Provides Updates on its Antiviral Drug Development Programs - Yahoo Finance
Tue, 08 Aug 2023
Cocrystal Pharma Selects Novel Oral Protease Inhibitor CDI-988 as Norovirus Lead - Yahoo Finance
Wed, 24 May 2023
HC Wainwright & Co. Maintains Cocrystal Pharma (COCP) Buy ... - Nasdaq
Mon, 24 Apr 2023
Cocrystal Pharma Appoints Pharma Industry Veteran Fred Hassan ... - BioSpace
Mon, 10 Apr 2023
PXD, TGTX and EH among pre-market gainers - Seeking Alpha
|
Financial Analysis |
| Price to Book Value: |
Neutral |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Neutral |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Neutral |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
10 (M) |
| Shares Float |
7 (M) |
|
% Held by Insiders
|
30 (%) |
|
% Held by Institutions
|
7.2 (%) |
|
Shares Short
|
15 (K) |
|
Shares Short P.Month
|
31 (K) |
Stock Financials |
|
EPS
|
-2.3 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
3.41 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
0 |
|
Return on Assets (ttm)
|
-27.8 |
|
Return on Equity (ttm)
|
-46.6 |
|
Qtrly Rev. Growth
|
0 |
|
Gross Profit (p.s.)
|
0 |
|
Sales Per Share
|
0 |
|
EBITDA (p.s.)
|
-1.92 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
-22 (M) |
|
Levered Free Cash Flow
|
-15 (M) |
Stock Valuations |
|
PE Ratio
|
-0.86 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
0.57 |
|
Price to Sales
|
0 |
|
Price to Cash Flow
|
-0.89 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
